Drug Development ProgressCapricor Therapeutics, Inc. continues to make progress in their CAP-1002 and Exosome programs.
Financial HealthThe company's solid cash position is believed to be sufficient to fund the upcoming Phase II trial for otenaproxesul.
Upcoming Clinical TrialsAntibe's lead drug, otenaproxesul, has shown strong efficacy and limited gastrointestinal side-effects in previous trials, presenting a competitive advantage in the pain management market.